[HTML][HTML] Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells
DV Mathews, WC Wakwe, SC Kim, MC Lowe… - American Journal of …, 2017 - Elsevier
Recently, newer therapies have been designed to more specifically target rejection in an
effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific
reagent, is associated with superior patient survival and graft function compared with
traditional therapy, but its adoption as a mainstay immunosuppressive therapy has been
tempered by increased rejection rates. It is essential that the underlying mechanisms
associated with this rejection be elucidated before belatacept is more widely used. To that …
effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific
reagent, is associated with superior patient survival and graft function compared with
traditional therapy, but its adoption as a mainstay immunosuppressive therapy has been
tempered by increased rejection rates. It is essential that the underlying mechanisms
associated with this rejection be elucidated before belatacept is more widely used. To that …